You are here: Industry Insights > Gilead Sciences

News List

Gilead Sciences Partners with the International AIDS Society to Champion Stigma-free HIV Care Services in Asia and Latin America prnasia
October 13, 2021
Gilead Sciences, Inc. today announced its partnership with IAS - the International AIDS Society - to expand the Me & My Healthcare Provider campaign to three locations in Asia...
Gilead Sciences to acquire MYR GmbH expresspharma
December 11, 2020
Gilead to acquire Hepcludex, a first-in-class entry inhibitor, for treatment of chronic hepatitis delta virus (HDV), after closing of transaction.
Gilead Sciences, AIDS Society of India survey highlights disruption in HIV care during COVID-19 expresspharma
December 01, 2020
Gilead Sciences and the AIDS Society of India announced findings from a pulse survey conducted to evaluate the impact of the COVID-19 pandemic on access and delivery of HIV care in the Asia Pacific.
Gilead Sciences' Pulse Survey Highlights Majority of People Living with HIV, Individuals at Risk and HIV Care Prescribers in Asia Pacific Experience Disruptions in HIV Care During COVID-19 Pandemic prnasia
November 30, 2020
Gilead Sciences, Inc. today announced findings from a pulse survey conducted to evaluate the impact of the COVID-19 pandemic on the access and delivery of care in HIV, which includes testing, treatment and prevention, in Asia Pacific.
Gilead Sciences Announces Recipients of its First Asia HIV Research Scholar Program prnasia
November 16, 2020
Gilead Sciences, Inc. today announced the recipients of its first Asia HIV Research Scholar Program. The Program awards up to US$130,000 over a period of two years to support innovative HIV scientific research led by early-career researchers from ...
Financial Report: Gilead contractpharma
October 29, 2020
Comments: HIV Product sales were $4.5 billion, up 8% primarily due to the continued strength of the HIV franchise and Biktarvy share continues to grow in the U.S. HCV Product sales declined 31% to $464 million impacted by delayed patient starts due to ...
Gilead Sciences acquires Immunomedics in $21bn deal pharmaceutical-technology
October 28, 2020
Gilead Sciences has completed the previously announced acquisition of cancer therapies developer Immunomedics for approximately $21bn.
Gilead Sciences Signs Agreement with Jounce Therapeutics contractpharma
September 03, 2020
Gilead Sciences Inc. has signed an agreement with Jounce Therapeutics Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively license its JTX-1811 program.
Dr Reddy’s signs licensing agreement with Gilead Sciences for remdesivir expresspharma
June 15, 2020
Dr Reddy’s will receive technology transfer from Gilead for manufacturing of this drug and needs to do the manufacturing scale-up and obtain regulatory approval for marketing of this drug in respective countries.
Health groups ask India to rescind Gilead’s patents for COVID-19 drug remdesivir expresspharma
May 15, 2020
Gilead’s three patents in India for remdesivir stem from 2009 when the drug was in development to treat Ebola.

Previous page 1 2 3 4 5 Next page